A case-control study of early-stage radiological markers of endothelial dysfunction and cardiovascular findings in patients with osteogenesis imperfecta: genotype–phenotype correlations
Author:
Evin Ferda1ORCID, Aydın Derya2ORCID, Levent Ertürk2ORCID, Özen Samim1ORCID, Darcan Şükran1ORCID, Gökşen Damla1ORCID
Affiliation:
1. Division of Pediatric Endocrinology, Department of Pediatrics, School of Medicine , Ege University , Izmir , Türkiye 2. Division of Pediatric Cardiology, Department of Pediatrics, School of Medicine , Ege University , Izmir , Türkiye
Abstract
Abstract
Objectives
Osteogenesis imperfecta (OI) is a disease caused by defective collagen synthesis. Collagen type 1 is found in many structures in the cardiovascular system. Endothelial dysfunction, which develops prior to the emergence of structural and clinical signs of atherosclerosis, is believed to play a key role in atherogenesis. Endothelial dysfunction may be detected presymptomatically by non-invasive radiologic methods, such as flow-mediated dilatation (FMD) and carotid intima-media thickness (CIMT). These modalities may provide early indicators of endothelial dysfunction. This cross-sectional comparative study aimed to investigate early-stage radiological markers of endothelial dysfunction and cardiovascular diseases in OI patients and healthy controls and to investigate the correlation of findings with OI genotype.
Methods
Thirty patients diagnosed with OI were paired with thirty healthy age- and gender-matched controls and echocardiogram findings were compared.
Results
None of the patients had known underlying cardiovascular disease. The mean age was 13.18 ± 2.91 years. According to Sillence classification, 15 patients had type 1 OI, 10 had type III, and 5 had type IV. Mean CIMT in the OI group was higher in the control group (OI group: 0.42 ± 0.06 vs. healthy controls: 0.34 ± 0.04 mm, p<0.01), and mean FMD percent was lower in the patient group (p<0.01). Left ventricular ejection fraction was 78.97 ± 10.32 vs. 77.56 ± 8.50 %, (OI group: 7.00 ± 3.06 vs. healthy controls: 12.14 ± 1.99, p=0.56), and fractional shortening was 42.68 ± 11.94 vs. 40.23 ± 7.99 %, (p=0.35), in OI patients and controls, respectively.
Conclusions
Pediatric patients with OI without clinical signs of cardiovascular abnormality had significantly worse CIMT and FMD findings than healthy controls. However, no difference was determined when comparing left ventricular ejection fraction or fractional shortening. OI patients may need to be screened for cardiovascular system complications starting from an early age.
Publisher
Walter de Gruyter GmbH
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health
Reference44 articles.
1. Forlino, A, Cabral, WA, Barnes, AM, Marini, JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7:540–57. https://doi.org/10.1038/nrendo.2011.81. 2. Rossi, V, Lee, B, Marom, R. Osteogenesis imperfecta: advancements in genetics and treatment. Curr Opin Pediatr 2019;31:708–15. https://doi.org/10.1097/mop.0000000000000813. 3. Palomo, T, Vilacą, T, Lazaretti-Castro, M. Osteogenesis imperfecta: diagnosis and treatment. Curr Opin Endocrinol Diabetes Obes 2017. https://doi.org/10.1097/med.0000000000000367. 4. Sillence, DO, Senn, A, Danks, DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet [Internet] 1979[cited 2021 May 19];16:101–16. https://doi.org/10.1136/jmg.16.2.101. 5. Marini, JC, Forlino, A, Bächinger, HP, Bishop, NJ, Byers, PH, De Paepe, A, et al.. Osteogenesis imperfecta. Nat Rev Dis Prim 2017;3:17052. https://doi.org/10.1038/nrdp.2017.52.
|
|